This inventor holds 1 USPTO granted patent and 2 published patent applications and 1 EPO patent. Top assignee: Novartis Ag. Active years: 2016.
Company Filing History:
Years Active: 2016
Title: Swann Gaulis: Innovator in Cancer Research
Introduction
Swann Gaulis is a notable inventor based in Basel, Switzerland. He has made significant contributions to the field of cancer research, particularly in the development of methods related to human double minute 2 inhibitors.
Latest Patents
Swann Gaulis holds a patent for "Markers associated with human double minute 2 inhibitors." This invention provides methods for monitoring differential gene expression of biomarkers to determine patient sensitivity to Human Double Minute inhibitors (MDM2i). Additionally, it includes methods for determining the sensitivity of a cell to an MDM2i by measuring biomarkers and methods for screening candidate MDM2i.
Career Highlights
Swann Gaulis is currently employed at Novartis AG, a leading global healthcare company. His work focuses on innovative solutions that enhance cancer treatment and patient outcomes.
Collaborations
He collaborates with notable colleagues, including Sebastien Jeay, who share a commitment to advancing cancer research.
Conclusion
Swann Gaulis is a prominent figure in the field of cancer research, with a patent that showcases his innovative approach to improving patient care. His contributions continue to influence the development of effective cancer therapies.